Apollo Endosurgery seals deal for Allergan's obesity intervention arm; Uroplasty expands coverage for incontinence treatment devices;

@FierceMedDev: St. Jude Medical to study neuromodulation combo treatment for back and leg pain. More | Follow @FierceMedDev

@MarkHFierce: Patients' attorneys say J&J either lost or wiped out vital docs about vaginal mesh implants vital to their lawsuits. Story | Follow @MarkHFierce

@MichaelGFierce: Researchers' pitch: An injectable, sustained-release rotator cuff treatment. News | Follow @MichaelGFierce

@GalenMoore: Boston hand-wringing alert: Celgene, Lilly back $100M VC fund for NY biotech startups. Story | Follow @GalenMoore

> Cernostics in Pittsburgh raised a $1.4 million Series B financing to speed up development of its diagnostic designed to predict the risk of esophageal cancer in patients with Barrett's esophagus. Item

> Uroplasty ($UPI), a maker of devices to treat incontinence, said it can take advantage of expanded coverage for a key treatment of overactive bladder from both Medicare and private insurers. Item

> Britain's National Health Service is under fire for not using an effective method to sterilize surgical instruments contaminated with variant Creutzfeldt-Jakob disease, a degenerative neurological disorder. Story

> Apollo Endosurgery, a 2012 Fierce 15 winner, has finalized its purchase of Allergan's ($AGN) obesity intervention business in a deal worth up to $110 million. Story

> Researchers are using crowdfunding to propel development of a device designed to help breast cancer patients and their doctors determine if chemotherapy is working. Story

Biotech News

@FierceBiotech: Organogenesis preps 'heart breaking' cuts as Medicare slashes reimbursement. More | Follow @FierceBiotech

@JohnCFierce: Hey, you VCs looking at getting into the NY fund, drop me a line with your thoughts. | Follow @JohnCFierce

@DamianFierce: As everyone goes public, Zafgen goes it alone, raises another $45M in Series E cash. Item | Follow @DamianFierce

@EmilyMFierce: ICYMI: Key hep C protein revealed, paving the way for new vaccines. News | Follow @EmilyMFierce

> 5AM Ventures has $250M and an eye out for early-stage biotechs. News

> Medicines Co. buys out Rempex's pipeline for hospital-acquired infections. Story

> Immunotherapy startup lands $120M Series A for cancer-killing drugs. More

Pharma News

@FiercePharma: Boehringer Ingelheim looks for a buyer for its troubled Bedford operation. News | Follow @FiercePharma

@EricPFierce: Will wonders--and AstraZeneca's patent battles over Prilosec--never cease? Apotex ordered to pay $76M. News | Follow @EricPFierce

@CarlyHFierce: Can Celgene, Eli Lilly and GE Ventures help turn NYC into a biotech hub? Story | Follow @CarlyHFierce

> Pfizer cutting 150 more jobs in Ireland in face of weak sales. More

> Teva has a 'clear strategy,' Desheh claims. Piece

Drug Delivery News

> Study: 'Worm-shaped' nanoparticles best at infiltrating breast cancer. More

> BioDelivery Sciences pushes diabetic pain gel to PhIII with FDA nod. News

> Danish nanorobots offer hot, cold delivery. Article

> Researchers' pitch: An injectable, sustained-release rotator cuff treatment. Piece

> Unilife bags Novartis deal for injectable tech. Story

> Bind founders publish data showing nanomed transport ability. Item

Diagnostics News

> LabCorp launch heightens crowding of BRCA predictive cancer test market. Story

> Biodesix grabs an $8.3M Series E for personalized lung cancer treatment test. Report

> Investors panic over BioReference Laboratories' reimbursement woes. Article

> U.K. team speeds brain cancer diagnostic process. News

> BioMérieux, Biocartis shut down molecular Dx development partnership. More

> Myriad Genetics inches closer to acquiring Crescendo Bioscience. Item

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.